TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37814020

Group type: EXPERIMENTAL
Intervention: Red meat meal consumption in women with RA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Red meat meal consumption in matched control group (women without RA)
Number of subjects: 44
Study: 37814061

Group type: EXPERIMENTAL
Intervention: pembrolizumab as standard of care
Number of subjects: 50
Study: 37814121

Group type: EXPERIMENTAL
Intervention: E7820, an anti-cancer sulfonamide
Number of subjects: 0
Study: 37814129

Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 32
Study: 37814224

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy (GDHT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 37814266

Group type: EXPERIMENTAL
Intervention: PA-telecoaching program (smartphone application with individual targets and feedback for 6 months, self-monitoring with a step counter for 9 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study: 37814285

Group type: EXPERIMENTAL
Intervention: Sarcopenia nursing guidance mobile application
Number of subjects: 120
Study: 37814306

Group type: EXPERIMENTAL
Intervention: Fotagliptin
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458

Group type: COMPARATOR
Intervention: Fotagliptin vs Placebo
Number of subjects: 458

Group type: COMPARATOR
Intervention: Alogliptin vs Placebo
Number of subjects: 458

Group type: COMPARATOR
Intervention: Fotagliptin vs Alogliptin
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Fotagliptin and Alogliptin
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 458
Study: 37814388

Group type: EXPERIMENTAL
Intervention: Full-body irradiation with 450 nm blue light
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Full-body irradiation with 415 nm blue light
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 87
Study: 37814541

Group type: EXPERIMENTAL
Intervention: Olme/Amlo/Rosu 20/5/5 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Olme/Amlo/Rosu 20/5/10 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amlo/Olme 20/5 mg
Number of subjects: 106
Study: 37814607

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study: 37814832

Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy
Number of subjects: 0
Study: 37814892

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering (target 110 to <130 mm Hg)
Number of subjects: 8259

Group type: COMPARATOR
Intervention: Standard treatment (SBP target 130 to <150 mm Hg)
Number of subjects: 8259
Study: 37814912

Group type: EXPERIMENTAL
Intervention: PB biopsy and preimplantation genetic testing for aneuploidy (PGT-A)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control group (no PB biopsy and PGT-A)
Number of subjects: 396
Study: 37815031

Group type: EXPERIMENTAL
Intervention: Rivaroxaban in patients with thrombocytopenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37815037

Group type: EXPERIMENTAL
Intervention: Loading dose alone regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Loading dose plus maintenance dose regimen
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Lower-dose regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Standard-dose regimen over 24 hours
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) maintenance regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Standard intramuscular (IM) maintenance regimen
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Short maintenance regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Standard (24 hours after birth) maintenance regimen
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Loading dose alone
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Loading dose plus maintenance therapy
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: IV maintenance regimen for 24 hours
Number of subjects: 3020

Group type: COMPARATOR
Intervention: IM maintenance regimen for 24 hours
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Short postpartum maintenance regimens
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Continuing for 24 hours after birth
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Higher-dose maintenance regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Lower-dose maintenance regimen
Number of subjects: 3020

Group type: EXPERIMENTAL
Intervention: Continuous infusion maintenance regimen
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Serial IV bolus regimen
Number of subjects: 3020
Study: 37815096

Group type: EXPERIMENTAL
Intervention: Exercise therapy for 24 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline physical tests (isometric muscle strength, muscle flexibility, vertical jump height, VAS scores)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Changes in physical test results
Number of subjects: 76
Study: 37815094

Group type: EXPERIMENTAL
Intervention: Tighter glycaemic control (≤ 5.0 to 5.1 mmol/L fasting plasma glucose; ≤ 6.7 to 7.4 mmol/L postprandial)
Number of subjects: 1731

Group type: EXPERIMENTAL
Intervention: Tighter glycaemic control
Number of subjects: 1731
Study: 37815115

Group type: EXPERIMENTAL
Intervention: Prolonged mild sleep restriction (SR)
Number of subjects: 78
Study: 37815254

Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 µg/min) for 20 minutes
Number of subjects: 139
Study: 37815398

Group type: EXPERIMENTAL
Intervention: 10 mg/kg telavancin
Number of subjects: 22
Study: 37815448

Group type: EXPERIMENTAL
Intervention: Phase I MRI protocols
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Modified MRI protocols after feedback
Number of subjects: 355
Study: 37815451

Group type: EXPERIMENTAL
Intervention: MRI examinations using standardized imaging protocols across six MRI scanners from three vendors at both 1.5 T and 3 T.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI proton density fat fraction (PDFF), liver stiffness at MR elastography (MRE), and visceral adipose tissue (VAT) measurements.
Number of subjects: 0
Study: 37815489

Group type: EXPERIMENTAL
Intervention: Plasma microbial cell-free DNA sequencing
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care testing
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combination of plasma microbial cell-free DNA sequencing and usual care testing
Number of subjects: 173
Study: 37815566

Group type: EXPERIMENTAL
Intervention: EHR reminders, outreach, and navigation (n=3455)
Number of subjects: 11980

Group type: EXPERIMENTAL
Intervention: EHR reminders and outreach (n=2569)
Number of subjects: 11980

Group type: EXPERIMENTAL
Intervention: EHR reminders (n=3254)
Number of subjects: 11980

Group type: COMPARATOR
Intervention: Usual care (n=2702)
Number of subjects: 11980
Study: 37815567

Group type: EXPERIMENTAL
Intervention: iodophor-CHG
Number of subjects: 801668

Group type: COMPARATOR
Intervention: mupirocin-CHG
Number of subjects: 801668
Study: 37815633

Group type: EXPERIMENTAL
Intervention: AYA-UNITE intervention, a 12-week group-based virtual exercise program incorporating strength training and aerobic activity.
Number of subjects: 0
Study: 37815684

Group type: EXPERIMENTAL
Intervention: Eribulin combined with cyclophosphamide (EC)
Number of subjects: 44
Study: 37815790

Group type: EXPERIMENTAL
Intervention: Antibiotic use in NICU
Number of subjects: 0
Study: 37815832

Group type: EXPERIMENTAL
Intervention: Intraventricular lavage
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard drainage
Number of subjects: 21
Study: 37815847

Group type: EXPERIMENTAL
Intervention: Encorafenib and cetuximab plus pembrolizumab
Number of subjects: 0
Study: 37815865

Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection
Number of subjects: 0
Study: 37815935

Group type: EXPERIMENTAL
Intervention: Universal decolonization with chlorhexidine and nasal povidone-iodine
Number of subjects: 28956

Group type: COMPARATOR
Intervention: Routine-care bathing
Number of subjects: 28956
Study: 37815957

Group type: EXPERIMENTAL
Intervention: Prophylactic psychopharmacological treatment (mainly first-generation antipsychotics)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Traditional medicine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Awareness of diagnostic status
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 154
Study: 37816010

Group type: EXPERIMENTAL
Intervention: Digital health interventions (DHI) including training on integrated COVID-NCD guidelines and use of a smartphone app-based telemedicine platform.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 150
Study: 37816169

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 718
Study: 37816198

Group type: EXPERIMENTAL
Intervention: PROStep intervention with weekly text message-based symptom surveys and passive activity monitoring using a wearable accelerometer; additional text-based active choice prompt in one arm
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PROStep intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no PROStep)
Number of subjects: 108
Study: 37816208

Group type: EXPERIMENTAL
Intervention: Tape Measurement (TM)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Bioimpedance Spectroscopy (BIS)
Number of subjects: 881
Study: 37816240

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37816249

Group type: EXPERIMENTAL
Intervention: Single criterion (∆K MAX >1D)
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Combination of K MAX and A F
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Combination of K MAX and P MIN
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Combination of K 2F and R mB
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: ABC criteria
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Wider 95% confidence intervals and requiring two parameters over 95CI
Number of subjects: 906

Group type: COMPARATOR
Intervention: Clinical studies
Number of subjects: 906
Study: 37816266

Group type: EXPERIMENTAL
Intervention: QTMP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CA-4
Number of subjects: 0
Study: 37816478

Group type: EXPERIMENTAL
Intervention: PASC subjects (n = 10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-PASC subjects (n = 13)
Number of subjects: 23
Study: 37816489

Group type: EXPERIMENTAL
Intervention: Silane-Adhesive treatment (application of a silane coupling agent after acid etching)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sandblast-Silane-Adhesive treatment (intra-oral sandblasting followed by silane application)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (No additional treatment)
Number of subjects: 116
Study: 37816552

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation combined with ERAS, at least 2 weeks before gastrectomy, including physical and respiratory training, nutritional support, and therapy and psychosocial treatment
Number of subjects: 368

Group type: COMPARATOR
Intervention: ERAS pathway treatment
Number of subjects: 368
Study: 37816557

Group type: EXPERIMENTAL
Intervention: Strategically deployed automated external defibrillators, CPR training of residents, recruitment of residents for a volunteer responder programme
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard OHCA emergency response including volunteer responder activation
Number of subjects: 26
Study: 37816561

Group type: EXPERIMENTAL
Intervention: Weekly text messaging encouraging exclusive breastfeeding plus in-person individual motivational interviews at weeks 2, 6, and 10.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard infant feeding counselling
Number of subjects: 52
Study: 37816636

Group type: EXPERIMENTAL
Intervention: Mothers with epilepsy
Number of subjects: 351

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Seizure control in mothers with epilepsy
Number of subjects: 351
Study: 37816943

Group type: EXPERIMENTAL
Intervention: Exercise-First
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sequential arm
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Simultaneous arm
Number of subjects: 150
Study: 37817124

Group type: EXPERIMENTAL
Intervention: Unilateral TBS (continuous TBS to the right and sham TBS to the left DLPFC)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Bilateral sequential TBS (continuous TBS to the right and intermittent TBS to the left DLPFC)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Bilateral sequential TBS
Number of subjects: 256
Study: 37817147

Group type: EXPERIMENTAL
Intervention: Day patient treatment (DP) after short inpatient (IP) stabilization
Number of subjects: 88

Group type: COMPARATOR
Intervention: Inpatient treatment (IP) as usual
Number of subjects: 88
Study: 37817237

Group type: EXPERIMENTAL
Intervention: Parent-based sexual health intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 37817255

Group type: EXPERIMENTAL
Intervention: Doxapram therapy
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study: 37817263

Group type: EXPERIMENTAL
Intervention: SP142 PD-L1 assay
Number of subjects: 232

Group type: COMPARATOR
Intervention: 22C3 PD-L1 assay
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PD-L1 (CD274) gene expression
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: PD-L1 IHC positivity
Number of subjects: 232
Study: 37817267

Group type: EXPERIMENTAL
Intervention: Behavioral sleep extension intervention (sleep coaching) for 8 weeks followed by monthly coaching for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education (control) for 8 weeks followed by monthly education for 2 months
Number of subjects: 0
Study: 37817285

Group type: EXPERIMENTAL
Intervention: ORZ-fortified canola oil
Number of subjects: 92

Group type: COMPARATOR
Intervention: Plain canola oil
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sunflower oil
Number of subjects: 92
Study: 37817565

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT) regimen consisting of 2 cycles of chemotherapy with DCF (docetaxel, cisplatin, and 5-fluorouracil) followed by preoperative CRT with oxaliplatin, continuous 5FU and radiotherapy (45 Gy in 25 fractions of 1.8 Gy, 5 fractions per week for 5 weeks)
Number of subjects: 33
Study: 37818166

Group type: EXPERIMENTAL
Intervention: Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD) diagnosis in male patients
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Pompe disease (PD) diagnosis in male and female patients
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Neurological symptoms and physical examination findings in DMD/BMD patients
Number of subjects: 589
Study: 37818279

Group type: EXPERIMENTAL
Intervention: Guideline-adherent treatments (exercise, education, dietary weight management)
Number of subjects: 2574

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: Various treatment pathways
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: Guideline-adherent pathways
Number of subjects: 2574

Group type: EXPERIMENTAL
Intervention: Overall treatment adherence
Number of subjects: 2574
Study: 37818304

Group type: EXPERIMENTAL
Intervention: mHealth intervention with 8 scripted messages and 8 unscripted messages, delivered via one voice message and one text message each week for 16 weeks.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: mHealth intervention (experimental group)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 488
Study: 37818403

Group type: EXPERIMENTAL
Intervention: Somapacitan (once-weekly)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Daily GH (control)
Number of subjects: 210
Study: 37818791

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care interventions delivered by healthcare professionals (general physicians, pharmacists, nurses, geriatricians)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interventions to improve appropriate polypharmacy
Number of subjects: 38
Study: 37819259

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 37819503

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Proposed adaptive dosing strategy
Number of subjects: 100
Study: 37819505

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W) or at week 0, week 4, then Q8W
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 37819539

Group type: EXPERIMENTAL
Intervention: Novel multi-active emollient
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard skin care (Control)
Number of subjects: 100
Study: 37819544

Group type: COMPARATOR
Intervention: Utstein criteria
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: CAHP Score
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Other scores (CREST, C-Graph, TTM, CAST, NULL-PLEASE, MIRACLE2)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Unfavorable neurological outcomes
Number of subjects: 658
Study: 37819552

Group type: EXPERIMENTAL
Intervention: Afterload technique
Number of subjects: 8189

Group type: COMPARATOR
Intervention: Direct technique
Number of subjects: 8189
Study: 37819652

Group type: EXPERIMENTAL
Intervention: Tension-free technique using nonabsorbable polytetrafluoroethylene mesh (Bard CruraSoft)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Crural sutures alone
Number of subjects: 145
Study: 37819656

Group type: EXPERIMENTAL
Intervention: Center-based cardiac rehabilitation (CBCR)
Number of subjects: 75
Study: 37819691

Group type: EXPERIMENTAL
Intervention: CAPABLE app (Cancer Patients Better Life Experience) used for a minimum of 3 and a maximum of 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard ICI therapy (control group)
Number of subjects: 36
Study: 37819836

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37819872

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 21

Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 21
Study: 37819936

Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine (100 mg/m2 on days 1, 8, and 15) combined with CHK1 inhibitor LY2880070 (50 mg orally twice daily on days 2-6, 9-13, and 16-20 of each 21-day cycle)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Organoid cultures derived from biopsies
Number of subjects: 11
Study: 37819954

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 37820029

Group type: COMPARATOR
Intervention: Secukinumab 300 mg followed by placebo
Number of subjects: 220

Group type: COMPARATOR
Intervention: Secukinumab 150 mg followed by placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 220
Study: 37820181

Group type: EXPERIMENTAL
Intervention: Hall technique preformed metal crown (HT)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Resin composite restoration (RC)
Number of subjects: 364
Study: 37820216

Group type: EXPERIMENTAL
Intervention: Low back complaints
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Upper limb problems
Number of subjects: 104
Study: 37820358

Group type: EXPERIMENTAL
Intervention: ROC training group (27 participants)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional therapy group (10 participants)
Number of subjects: 37
Study: 37820539

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Continuing smoking
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Quitting smoking (adjusted for confounders)
Number of subjects: 2751
Study: 37820844

Group type: EXPERIMENTAL
Intervention: PEMF + exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham PEMF + exercise
Number of subjects: 80
Study: 37821023

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2188

Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 2188

Group type: COMPARATOR
Intervention: Family income <$40,000
Number of subjects: 2188

Group type: COMPARATOR
Intervention: Family income $40,000-$79,999
Number of subjects: 2188
Study: 37821096

Group type: COMPARATOR
Intervention: 0 mg CBD (0:1 CBD:THC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10 mg CBD (1:1 CBD:THC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 20 mg CBD (2:1 CBD:THC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 30 mg CBD (3:1 CBD:THC)
Number of subjects: 46
Study: 37821122

Group type: EXPERIMENTAL
Intervention: Ultrasound guided deposit lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (lavage+steroid)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Sham lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (sham lavage+steroid)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham lavage plus subacromial injection of 10 mL 1% lidocaine hydrochloride (sham)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 220
Study: 37821131

Group type: EXPERIMENTAL
Intervention: 200 mg potassium canrenoate every 6 hours until organ procurement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Matching placebo every 6 hours until organ procurement
Number of subjects: 36
Study: 37821166

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 5403

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 5403